Technology
Health
Biotechnology

Hemispherx

$0.13
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0014 (-1.07%) Today
+$0.0003 (0.23%) After Hours

Why Robinhood?

You can buy or sell Hemispherx and other stocks, options, ETFs, and crypto commission-free!

About

Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. Read More The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.

Employees
33
Headquarters
Ocala, Florida
Founded
1966
Market Cap
6.32M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.27M
High Today
$0.142
Low Today
$0.12
Open Price
$0.142
Volume
1.53M
52 Week High
$0.35
52 Week Low
$0.12

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Medical
Cancer Prevention
Pharmaceutical
US

News

Yahoo FinanceMay 13

Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma

ORLANDO, FL, May 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announced it is making progress toward the opening of Roswell Park Comprehensive Cancer Center’s clinical study incorporating Ampligen as part of a treatment combination for prostate cancer. CEOLIVE has been covering Hemispherx for two years and ...

2,214
Yahoo FinanceMay 13

Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center

OCALA, Fla., May 13, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announced progress toward the opening of Roswell Park Comprehensive Cancer Center’s clinical study incorporating Ampligen as part of a treatment combination for prostate cancer. Roswell Park now has FDA authorization to proceed with its Phase 2 study investigating the ...

2,800
NasdaqMay 8

Hemispherx Biopharma's CEO to Attend BioFlorida Inc.’s 2019 Celebration of Biotechnology

Hemispherx Biopharma's CEO to Attend BioFlorida Inc.'s 2019 Celebration of Biotechnology OCALA, Fla., May 08, 2019 (GLOBE NEWSWIRE) -- (NYSE American:HEB) — Hemispherx Biopharma Inc.'s CEO Thomas K. Equels will be attending the 2019 Celebration of Biotechnology where he'll meet with investors and industry representatives to discuss the company's recent successes and plans for the future. Hemispherx is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types...

2,147

Earnings

-$0.07
-$0.05
-$0.02
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.05 per share
Actual
-$0.07 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.